Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
145 hedge funds and large institutions have $700M invested in Lumos Pharma, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 51 increasing their positions, 38 reducing their positions, and 20 closing their positions.
105% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 20
97% more call options, than puts
Call options by funds: $68.8M | Put options by funds: $35M
34% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 38
17% more funds holding
Funds holding: 124 → 145 (+21)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less capital invested
Capital invested by funds: $754M → $700M (-$53.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
+$19.2M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$18.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.5M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$14.6M |
| 5 |
First Eagle Investment Management
New York
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$27M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$11.8M |
| 3 |
CNB
City National Bank
Beverly Hills,
California
|
-$10M |
| 4 |
PC
PointState Capital
New York
|
-$9.68M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.68M |
LUMO Hedge Fund Activity: Q2 2015 in Review
145 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q2 2015, worth a combined $700M — down 7.1% from $754M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new LUMO positions and 20 closed out — a net gain of 21 holders — while 51 added to existing stakes and 38 trimmed.
The largest buyer was Gotham Asset Management, adding an estimated $19.2M. The largest seller was OrbiMed, exiting entirely with an estimated $27M sold.
- 145 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q2 2015, up from 124 in Q1 2015.
- Funds reported $700M of Lumos Pharma, Inc. Common Stock stock for Q2 2015, down 7.1% quarter-over-quarter.
- 41 funds opened new Lumos Pharma, Inc. Common Stock positions in Q2 2015 and 20 closed out, a net change of +21 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q2 2015 was Gotham Asset Management, an estimated $19.2M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q2 2015 was OrbiMed, an estimated $27M sold.
Based on aggregated 13F filings for Q2 2015.